<i>NCDN</i> is a Potential Biomarker and Therapeutic Target for Glioblastoma

Huang, Xiaokai; Xu, Chengwu; Dai, Haipeng; Yang, Jianchun; Huang, Tingting; Chen, Shuan; Qi, Lingxin; Ruan, Jichen; Wang, Juxiang

doi:10.7150/jca.90535



International Journal of Biological Sciences

International Journal of Medical Sciences

Theranostics

Journal of Genomics

Nanotheranostics

Global reach, higher impact

Full Text | PDF

J Cancer 2024; 15(4):1067-1076. doi:10.7150/jca.90535 This issue Cite

Research Paper

NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma

Xiaokai Huang^1,2*, Chengwu Xu^1*, Haipeng Dai^3*, Jianchun Yang¹, Tingting Huang^1,2, Shuan Chen¹, Lingxin Qi¹, Jichen Ruan^1,2, Juxiang Wang^1,2✉

1. Department of Hematology, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
2. The Key Laboratory of Pediatric Hematology and oncology Diseases of Wenzhou, the Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
3. Department of Pediatric Surgery, The Second Affiliated Hospital and Yuying Children's Hospital of Wenzhou Medical University, Wenzhou 325027, Zhejiang, China.
^*These authors contribute equally to this work.

Citation:

Huang X, Xu C, Dai H, Yang J, Huang T, Chen S, Qi L, Ruan J, Wang J. NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma. J Cancer 2024; 15(4):1067-1076. doi:10.7150/jca.90535. https://www.jcancer.org/v15p1067.htm

Other styles

Abstract

Background: Glioblastoma (GBM) is a type of central nervous system malignancy. In our study, we determined the effect of NCDN in GBM patients through The Cancer Genome Atlas (TCGA) data analysis, and studied the effects of NCDN on GBM cell function to estimate its potential as a therapeutic target.

Methods: Gene expression profiles of glioblastoma cohort were acquired from TCGA database and analyzed to look for central genes that may serve as GBM therapeutic targets. Then the cell function of NCDN in glioblastoma cell was explored through in vitro cell experiments.

Results: Through gene ontology (GO) analysis, weighted gene co-expression network analysis (WGCNA), and survival analysis, we identified three key genes (NCDN, PAK1 and SPRYD3) associated with poor prognosis in glioblastoma. In vitro experiments showed impaired cell migration, apoptosis, and cell cycle arrest in NCDN knockdown cells.

Conclusion: NCDN affects the progress and prognosis of glioblastoma by promoting cell migration and inhibiting apoptosis.

Keywords: glioblastoma, NCDN, TCGA data analysis, migration, apoptosis

Citation styles

APA

Huang, X., Xu, C., Dai, H., Yang, J., Huang, T., Chen, S., Qi, L., Ruan, J., Wang, J. (2024). NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma. Journal of Cancer, 15(4), 1067-1076. https://doi.org/10.7150/jca.90535.

ACS

Huang, X.; Xu, C.; Dai, H.; Yang, J.; Huang, T.; Chen, S.; Qi, L.; Ruan, J.; Wang, J. NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma. J. Cancer 2024, 15 (4), 1067-1076. DOI: 10.7150/jca.90535.

NLM

CSE

Huang X, Xu C, Dai H, Yang J, Huang T, Chen S, Qi L, Ruan J, Wang J. 2024. NCDN is a Potential Biomarker and Therapeutic Target for Glioblastoma. J Cancer. 15(4):1067-1076.

This is an open access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0/). See http://ivyspring.com/terms for full terms and conditions.